{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:15:41Z","timestamp":1788156941347,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor inhibitors (EGFRIs) -related rash is prevalent, and honeysuckle therapy (HT) has been extensively utilized for skin rash. However, high-quality clinical evidence supporting the use of HT for EGFRIs-related rash remains scarce. This study aims to systematically assess the prophylactic and therapeutic effectiveness and safety of HT in managing EGFRIs-related rash.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was performed in six electronic databases from their inception to 25 March 2025 to identify eligible randomized controlled trials (RCTs). Methodological risk of bias was evaluated using the Cochrane RoB 1.0 tool, and the certainty of evidence was graded using the GRADE approach. Meta-analyses were implemented using RevMan 5.4 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven RCTs with a total of 534 participants were enrolled. Prophylactically, HT significantly reduced \u2265 Grade 2 rash incidence (RR = 0.43, 95% CI: 0.29\u20130.65,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001; 2 RCTs) and delayed time to rash onset (MD = 8.87\u00a0days, 95% CI: 5.30\u201312.44\u00a0days,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001; 1 RCT). No significant differences were detected in overall rash incidence (RR = 0.84, 95% CI: 0.69\u20131.01,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.07; 2 RCTs) or rash duration (MD = \u22124.43\u00a0days, 95% CI: \u22129.69 to 0.83 days,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.10; 1 RCT). For therapeutic use, HT significantly improved the clinical effective rate of rash management (RR = 1.35, 95% CI: 1.13\u20131.62,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001; 5 RCTs). Subgroup analyses confirmed consistent efficacy across single-botanical drug\/compound formulations and topical\/combined oral\u2013topical administration routes. HT also improved quality of life. No severe HT-related adverse events were documented among studies that reported safety outcomes. Evidence certainty was low to very low.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Due to the low certainty and very low certainty of evidence, HT may alleviate severe EGFRIs-related rash and improve therapeutic response. High-quality, large-scale, multicenter RCTs with standardized honeysuckle botanical drug formulations, dosages, and outcome measures are urgently needed to validate these preliminary findings and improve clinical generalizability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , Identifier CRD420251035535.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1875649","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:40:17Z","timestamp":1788154817000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of honeysuckle therapy for epidermal growth factor receptor inhibitor-related rash: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Li-Feng","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Lung Neoplasms, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nursing, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Cancer Prevention and Therapy","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"Department of Integrated Traditional Chinese and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lung Neoplasms, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/exd.14728","article-title":"Persistent alteration of the skin microbiome in patients with skin rash after receiving EGFR inhibitor treatment","volume":"32","author":"Ashida","year":"2023","journal-title":"Exp. Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"103811","DOI":"10.1016\/j.bioorg.2020.103811","article-title":"A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy","volume":"99","author":"Ayati","year":"2020","journal-title":"Bioorg. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1007\/s00520-016-3231-1","article-title":"EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections","volume":"24","author":"Braden","year":"2016","journal-title":"Support. Care Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1277283","DOI":"10.3389\/fphar.2023.1277283","article-title":"Lonicerae Japonicae caulis: a review of its research progress of active metabolites and pharmacological effects","volume":"14","author":"Cao","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/1472-6882-12-226","article-title":"Wound repair and anti-inflammatory potential of Lonicera japonica in excision wound-induced rats","volume":"12","author":"Chen","year":"2012","journal-title":"BMC Complement. Altern. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"102167","DOI":"10.1016\/j.ctim.2019.08.001","article-title":"Chinese herbal medicine for epidermal growth factor receptor inhibitor-induced skin rash in patients with malignancy: an updated meta-analysis of 23 randomized controlled trials","volume":"47","author":"Chen","year":"2019","journal-title":"Complement. Ther. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"174522","DOI":"10.1016\/j.ejphar.2021.174522","article-title":"Protective effect of cynaroside on sepsis-induced multiple organ injury through Nrf2\/HO-1-dependent macrophage polarization","volume":"911","author":"Feng","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/13543784.2024.2349287","article-title":"Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy","volume":"33","author":"Gonz\u00e1lez","year":"2024","journal-title":"Expert. Opin. Investig. Drugs."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.05.013","article-title":"Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer","volume":"134","author":"Hayashi","year":"2019","journal-title":"Lung Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"953205","DOI":"10.3389\/fphar.2022.953205","article-title":"Best practice in the chemical characterisation of extracts used in pharmacological and toxicological research-The ConPhyMP-Guidelines","volume":"13","author":"Heinrich","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.explore.2018.11.001","article-title":"Clinical experience of Chinese herbal medicine ameliorates dermatologic events from epidermal growth factor receptor inhibitors for lung cancer: a case series","volume":"15","author":"Hung","year":"2019","journal-title":"Explore (NY)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.1007\/s00520-022-07257-2","article-title":"Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients","volume":"30","author":"Ibraheim","year":"2022","journal-title":"Support. Care Cancer."},{"key":"B15","first-page":"243","article-title":"Efficacy observation of Lonicera japonica solution wet dressing in the treatment of cetuximab-induced acneiform rash","volume":"26","author":"Jiang","year":"2015","journal-title":"China Pharm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e35778","DOI":"10.1002\/cncr.35778","article-title":"Updates on the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer","volume":"131","author":"Kim","year":"2025","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejphar.2006.01.021","article-title":"Antioxidant enzymes activity involvement in luteolin-induced human lung squamous carcinoma CH27 cell apoptosis","volume":"534","author":"Leung","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"B18","first-page":"35","article-title":"Clinical observation on the treatment of targeted drug-related rashes by external flower washing combined with internal administration","volume":"39","author":"Li","year":"2017","journal-title":"Hubei J. Traditional Chin. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"15347354221086663","DOI":"10.1177\/15347354221086663","article-title":"Efficacy of prophylactic Traditional Chinese medicine on skin toxicity of afatinib in EGFR mutation-positive advanced lung adenocarcinoma: a single-center, prospective, double-blinded, randomized-controlled pilot trial","volume":"21","author":"Li","year":"2022","journal-title":"Integr. Cancer. Ther."},{"key":"B20","first-page":"387","article-title":"The decoction of honeysuckle relieves the rash caused by cetuximab","author":"Lin","year":"2012"},{"key":"B21","doi-asserted-by":"publisher","first-page":"835166","DOI":"10.3389\/fphar.2022.835166","article-title":"Reducing acneiform rash induced by EGFR inhibitors with honeysuckle therapy: a prospective, randomized, controlled study","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.13194\/j.issn.1673-842x.2020.08.047","article-title":"Observation on the effect of compound honeysuckle decoction combined with chlortetracycline eye ointment on the severity and duration of skin rash caused by EGFRIs","volume":"22","author":"Lu","year":"2020","journal-title":"J. Liaoning Univ. Trad. Chin. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2174\/1568026620666200303123102","article-title":"Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors","volume":"20","author":"Sabbah","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"105393","DOI":"10.1016\/j.bioorg.2021.105393","article-title":"Epidermal growth factor receptor inhibitors as potential anticancer agents: an update of recent progress","volume":"116","author":"Sharma","year":"2021","journal-title":"Bioorg. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fphar.2016.00012","article-title":"Spectrum-effect relationships between chemical fingerprints and antibacterial effects of Lonicerae Japonicae flos and Lonicerae flos base on UPLC and microcalorimetry","volume":"7","author":"Shi","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1200\/JCO.2015.63.4154","article-title":"Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L","volume":"34","author":"Urata","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.13241\/j.cnki.pmb.2017.27.014","article-title":"Clinical efficacy of compound honeysuckle decoction hot and humid joint fusidic acid cream in treatment of targeted drugs-induced rash","volume":"17","author":"Wu","year":"2017","journal-title":"Prog. Mod. Biomed."},{"key":"B29","doi-asserted-by":"publisher","first-page":"eabq7074","DOI":"10.1126\/scitranslmed.abq7074","article-title":"Topical JAK inhibition ameliorates EGFR inhibitor-induced rash in rodents and humans","volume":"16","author":"You","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1111\/jocd.15704","article-title":"Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: a review","volume":"22","author":"Yuan","year":"2023","journal-title":"J. Cosmet. Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3761\/j.issn.0254-1769.2010.04.007","article-title":"The efficacy of wet compress with flos lonicerae for cetuximab correlative erythra","volume":"45","author":"Zhang","year":"2010","journal-title":"Chin. J. Nurs."},{"key":"B32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4103\/wjtcm.wjtcm_32_19","article-title":"Efficacy of Traditional Chinese medicine in the treatment of rash caused by epidermal growth factor receptor inhibitors: a frequency statistics and meta-analysis","volume":"5","author":"Zheng","year":"2019","journal-title":"World J. Trad. Chin. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1013992","DOI":"10.3389\/fphar.2022.1013992","article-title":"Systematic review of Lonicerae Japonicae flos: a significant food and traditional Chinese medicine","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/cr.2014.130","article-title":"Honeysuckle-encoded atypical microRNA2911 directly targets influenza A viruses","volume":"25","author":"Zhou","year":"2015","journal-title":"Cell Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1875649\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:40:23Z","timestamp":1788154823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1875649\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":34,"alternative-id":["10.3389\/fphar.2026.1875649"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1875649","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1875649"}}